Fractyl Health (GUTS) vs iBio (IBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Fractyl Health (GUTS) over the past year, gaining 2.5% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($58.6 million vs $56.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GUTS | IBIO |
|---|---|---|
| Share price | $4.42 | $0.871 |
| Market cap | $58.63M | $56.01M |
| 1-day change | +4.49% | -5.33% |
| YTD return | -83.98% | -54.87% |
| 1-year return | -74.82% | +2.47% |
| 5-year return | — | -99.81% |
| EPS (TTM) | $-10.56 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.34 | $3.82 |
| 52-week low | $4.14 | $0.78 |
| Distance from 52-week high | -84.94% | -77.20% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1266.52% | +553.27% |
| Average volume | 156.16K | 727.93K |
| Shares outstanding | 13.26M | 64.31M |
| Employees | 100 | 23 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed GUTS by 77.3 percentage points over the past year.
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
GUTS vs IBIO FAQ
Which is bigger, Fractyl Health or iBio?
Fractyl Health (GUTS) is larger, with a market capitalization of $58.63M compared with $56.01M for iBio (IBIO).
Which stock has performed better over the past year, GUTS or IBIO?
IBIO returned +2.47% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Fractyl Health and iBio in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Fractyl Health and Biotechnology: Pharmaceutical Preparations for iBio.